Capital International Investors Decreases Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Capital International Investors decreased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 50.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 126,230 shares of the biotechnology company's stock after selling 129,641 shares during the quarter. Capital International Investors owned 0.10% of Arrowhead Pharmaceuticals worth $2,373,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. World Investment Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 3.8% in the 3rd quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company's stock valued at $371,000 after buying an additional 700 shares during the period. Xponance Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 4.5% during the fourth quarter. Xponance Inc. now owns 17,400 shares of the biotechnology company's stock worth $327,000 after buying an additional 744 shares during the period. Summit Investment Advisors Inc. raised its holdings in Arrowhead Pharmaceuticals by 2.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 37,994 shares of the biotechnology company's stock valued at $714,000 after acquiring an additional 803 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in Arrowhead Pharmaceuticals by 10.2% in the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company's stock worth $243,000 after acquiring an additional 1,195 shares during the last quarter. Finally, Van ECK Associates Corp grew its holdings in Arrowhead Pharmaceuticals by 72.3% during the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 1,250 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on ARWR. B. Riley reaffirmed a "buy" rating and set a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Chardan Capital reiterated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of "Hold" and an average price target of $41.44.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR traded down $0.09 on Friday, reaching $13.25. The company's stock had a trading volume of 862,735 shares, compared to its average volume of 1,443,607. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $30.41. The stock has a market capitalization of $1.82 billion, a P/E ratio of -2.56 and a beta of 0.99. The stock's 50-day moving average is $14.57 and its two-hundred day moving average is $18.40. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). As a group, sell-side analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Insider Buying and Selling

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. This represents a 1.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 275,880 shares of company stock valued at $4,034,037 over the last three months. 4.30% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.